Mark For: VENOGLOBULIN® trademark registration is intended to cover the categories of pharmaceutical preparations in the nature of gammaglobulin preparations for use in the treatment of primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplant in adults, chronic B-cell lymphocytic leukemia, pediatric HIV infection, chronic inflammatory demyelinating polyneuropathy, post-transfusion purpura, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneurophathy, anemia because of parvovirus B19, patients with stable multiple myeloma who are at high risk for recurrent infection, cytomegalovirus (CMV)-negative recipients of CMV-positive organs, hypogammaglobulinemic neonates with risk factor for infection or morbidity, intractable epilepsy, systemic vasculitic syndromes, warm-type automimmune hemolytic anemia, neonatal alloimmune thrombocytopenia when unresponsive to other treatments, immune-mediated neutropenia, decompensation in myasthenia gravis, dermatomyositis, polymyosits, thrombocytopenia when severe and unresponsive to other treatments. [all]
Status
2022-09-08 UTC
DEAD REGISTRATION Cancelled Invalidated
The trademark application was registered, but subsequently it was cancelled or invalidated and removed from the registry.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
Yes
Intent To Use
No
Filed ITU
Yes
44D Filed
No
44E Current
Yes
66A Current
No
Current Basis
No
No Basis
No
Cancellation Code
2
Domestic Representative
Lynn A Sullivan
Attorney Name
Lynn A Sullivan
Law Office Assigned
M60
Employee Name
DEFORD, JEFFREY S
Timeline
1987-02-26
Date of First Use
1987-02-26
Date of Use In Commerce
2001-03-01
Application Filed
2003-02-25
Published
2003-02-25
Published for Opposition
2003-05-20
Trademark Registered
2008-03-14
Location: SCANNING ON DEMAND
2009-12-26
Cancelled
2009-12-26
Status: Dead/Cancelled
2009-12-26
Status: Registration cancelled because registrant did not file an acceptable declaration under Section 8. To view all documents in this
LYNN A SULLIVAN LEYDIG VOIT & MAYER LTD TWO PRUDENTIAL PLAZA SUITE 4900 CHICAGO ILLINOIS 60601-6780
Good, Services, and Codes
(CANCELLED) IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations in the nature of gammaglobulin preparations for use in the treatment of primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplant in adults, chronic B-cell lymphocytic leukemia, pediatric HIV infection, chronic inflammatory demyelinating polyneuropathy, post-transfusion purpura, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneurophathy, anemia because of parvovirus B19, patients with stable multiple myeloma who are at high risk for recurrent infection, cytomegalovirus (CMV)-negative recipients of CMV-positive organs, hypogammaglobulinemic neonates with risk factor for infection or morbidity, intractable epilepsy, systemic vasculitic syndromes, warm-type automimmune hemolytic anemia, neonatal alloimmune thrombocytopenia when unresponsive to other treatments, immune-mediated neutropenia, decompensation in myasthenia gravis, dermatomyositis, polymyosits, thrombocytopenia when severe and unresponsive to other treatments. FIRST USE: 19870226. FIRST USE IN COMMERCE: 19870226
International Codes:
5
U.S. Codes:
006,018,044,046,051,052
Type Code
Type
GS0051
Pharmaceutical preparations in the nature of gammaglobulin preparations for use in the treatment of primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplant in adults, chronic B-cell lymphocytic leukemia, pediatric HIV infection, chronic inflammatory demyelinating polyneuropathy, post-transfusion purpura, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneurophathy, anemia because of parvovirus B19, patients with stable multiple myeloma who are at high risk for recurrent infection, cytomegalovirus (CMV)-negative recipients of CMV-positive organs, hypogammaglobulinemic neonates with risk factor for infection or morbidity, intractable epilepsy, systemic vasculitic syndromes, warm-type automimmune hemolytic anemia, neonatal alloimmune thrombocytopenia when unresponsive to other treatments, immune-mediated neutropenia, decompensation in myasthenia gravis, dermatomyositis, polymyosits, thrombocytopenia when severe and unresponsive to other treatments
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.